Wegovy was approved by the FDA to reduce the risk of major cardiovascular events in obese or overweight adults with established cardiovascular disease.
Wegovy has been shown to reduce the risk of major adverse cardiac events by 20%, cardiovascular death by 15%, and death from any cause by 19%. [ more ]
Senate Committee Investigates Ozempic and Wegovy Costs
The Senate Committee is investigating Novo Nordisk's high prices for Ozempic and Wegovy medications, urging the company to consider lowering costs for better accessibility. [ more ]
The foundation behind Ozempic maker Novo Nordisk is funding an Nvidia-backed AI supercomputer project
Novo Nordisk is investing in an AI supercomputer through collaboration with Nvidia for drug discovery and other scientific advancements.
The Novo Nordisk Foundation's investment in the AI supercomputer is aimed at accelerating groundbreaking scientific discoveries and fostering collaboration between academia and industry. [ more ]
Denmark's new Nvidia AI supercomputer will come online this year
Nvidia and Novo Nordisk are collaborating to establish an advanced AI supercomputer in Denmark named Gefion, boosting research in various fields.
The supercomputer Gefion, powered by Nvidia's GPUs, will support the Danish Center for AI Innovation and be hosted using 100% renewable energy. [ more ]
Tracy Morgan Says He Actually Managed to Gain Weight on Ozempic With Superhuman Eating Abilities
Tracy Morgan claims to have out-eaten Ozempic, gaining 40 pounds despite its appetite-limiting effects.
Ozempic from Novo Nordisk is gaining popularity for weight loss treatment among celebrities, despite concerns about its long-term effectiveness and safety. [ more ]
Study shows no evidence of suicidal thoughts caused by Ozempic, Wegovy
A large U.S. study found no evidence of a link between Novo Nordisk's Ozempic and Wegovy and an increase in suicidal thoughts.
The study found that semaglutide, the active ingredient in Ozempic and Wegovy, actually had a lower risk of new and recurrent suicidal thoughts compared to other medications for weight loss or diabetes. [ more ]
Five hundred new jobs coming in Chartres, south of Paris
Danish pharmaceutical giant Novo Nordisk is investing â¬2.1 billion in a French production site to expand the capacity and manufacturing of its anti-obesity drug.
Novo Nordisk's Semaglutide medication, originally meant for diabetes, is also effective against obesity and has massive global potential.
Goldman Sachs predicts that the global market for anti-obesity medication could reach $100 billion by 2030. [ more ]